Helix Biopharma Corp.
HBP.TO
TSX
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 36.34% | -12.27% | 1.11% | 74.61% | -185.81% |
| Total Depreciation and Amortization | -66.67% | 50.00% | -51.72% | 31.82% | -24.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -17.89% | -55.75% | 161.71% | -105.91% | 24,432.04% |
| Change in Net Operating Assets | 157.52% | -66.21% | -57.02% | -36.55% | 53.90% |
| Cash from Operations | 51.38% | -46.88% | -4.90% | -15.43% | 34.11% |
| Capital Expenditure | -- | 100.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -100.00% | 30.51% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -100.00% | 6.78% | 493.33% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -96.29% | -- | -- | -36.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.99% | -96.29% | -- | -- | -36.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | 410.17% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 47.51% | -172.45% | 299.15% | -330.60% | -37.70% |